Imperial College London
Alternate

ProfessorMarie-ClaudeBoily

Faculty of Medicine, School of Public Health

Professor of Mathematical Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 3263mc.boily

 
 
//

Location

 

LG26Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Gottlieb:2019:10.1016/j.vaccine.2017.03.074,
author = {Gottlieb, SL and Giersing, B and Boily, M-C and Chesson, H and Looker, KJ and Schiffer, J and Spicknall, I and Hutubessy, R and Broutet, N and WHO, HSV Vaccine Impact Modelling Meeting Working Group},
doi = {10.1016/j.vaccine.2017.03.074},
journal = {Vaccine},
pages = {7336--7345},
title = {Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.},
url = {http://dx.doi.org/10.1016/j.vaccine.2017.03.074},
volume = {37},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Development of a vaccine against herpes simplex virus (HSV) is an important goal for global sexual and reproductive health. In order to more precisely define the health and economic burden of HSV infection and the theoretical impact and cost-effectiveness of an HSV vaccine, in 2015 the World Health Organization convened an expert consultation meeting on HSV vaccine impact modelling. The experts reviewed existing model-based estimates and dynamic models of HSV infection to outline critical future modelling needs to inform development of a comprehensive business case and preferred product characteristics for an HSV vaccine. This article summarizes key findings and discussions from the meeting on modelling needs related to HSV burden, costs, and vaccine impact, essential data needs to carry out those models, and important model components and parameters.
AU  - Gottlieb,SL
AU  - Giersing,B
AU  - Boily,M-C
AU  - Chesson,H
AU  - Looker,KJ
AU  - Schiffer,J
AU  - Spicknall,I
AU  - Hutubessy,R
AU  - Broutet,N
AU  - WHO,HSV Vaccine Impact Modelling Meeting Working Group
DO  - 10.1016/j.vaccine.2017.03.074
EP  - 7345
PY  - 2019///
SN  - 0264-410X
SP  - 7336
TI  - Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
T2  - Vaccine
UR  - http://dx.doi.org/10.1016/j.vaccine.2017.03.074
UR  - http://hdl.handle.net/10044/1/54800
VL  - 37
ER  -
Download